Company Overview and News

 
Company news: Suven Life Sciences

2018-09-25 thehindubusinessline
Suven Life Sciences on Tuesday informed the exchanges of the receipt of one product patent from Canada and another from Sri Lanka for the new chemical entity (NCE) for treatment of disorders associated with neuro-degenerative diseases. The patents are valid through 2034 and 2026, respectively. The granted claims of the patents include the class of selective H3 and 5-HT6 compounds respectively, and are being developed as therapeutic agents for neurodegenerative disorders such as Alzheimer's disease, attention-deficit hyperactivity disorder (ADHD), Huntington’s disease, Parkinson’s disease and Schizophrenia, as well as sleep disorders like Narcolepsy, etc.
505200 ECQRY 530239 EICHERMOT SUVEN

 
An evening walk down Dalal Street | Bulls heave a sigh of relief, Sensex up 347 points; Nifty above 11,050

2018-09-25 moneycontrol
After days of relentless correction, bulls can finally heave a sigh of relief today. The Nifty has managed to reclaim 11,000 and end above it, while the Sensex surged 347 points.
YESBANK 532234 532121 532648 530239 YYBKY DENABANK NATIONALUM SUVEN 532401 VIJAYABANK

 
Suven Life Sciences surges 5% on getting product patents from Sri Lanka, Canada

2018-09-25 moneycontrol
Shares of Suven Life Sciences added 5.2 percent intraday Tuesday after company granted 1 product patent each in Sri Lanka and Canada.
530239 SUVEN

 
Suven Life Sciences Limited - Press Release

2018-09-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
530239 SUVEN

 
Suven Life Sciences Limited - Press Release

2018-09-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
530239 SUVEN

 
Broker's call: Suven Life (Buy)

2018-08-30 thehindubusinessline
Suven Life Sciences is a bio-pharmaceutical company. The company is engaged in the business of manufacture and sale of bulk drugs and intermediaries.
530239 SUVEN

 
Suven Life Sciences Limited - Press Release

2018-08-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
530239 SUVEN

 
Suven Life Sciences touches 52-week high on securing product process patents in Canada, USA

2018-08-23 moneycontrol
Shares of Suven Life Sciences touched 52-week high of Rs 267, rising 3.5 percent intraday Thursday as company secured product and process patents in Canada and USA.
530239 SUVEN

 
Suven Life Sciences Limited - Spurt in Volume

2018-08-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
530239 SUVEN

 
Suven Life Sciences Limited - Updates

2018-08-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
530239 SUVEN

 
Suven Life Sciences Limited - Press Release

2018-08-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
530239 SUVEN

 
Suven Life Sciences Limited - Spurt in Volume

2018-08-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
530239 SUVEN

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...